FINEARTS-HF
2024
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
In 6,001 patients with heart failure and an ejection fraction ≥ 40 %, finerenone reduced worsening-heart-failure events and cardiovascular death compared with placebo.
Result
Efficacy: Total worsening-HF events + CV deathrate ratio 0.84
Below 1 favours finerenone, above 1 favours placebo.
Also reported: CV death alone not significant; hyperkalaemia ~ 10 %.
- Subtopic
- MRA
- Design
- Double-blind RCT
- Relevance
- Important: one of several pillars.
- Cited in
- ESC 2026 HFACC/AHA 2026 CKM
- Source
- Solomon SD, et al. N Engl J Med. 2024;391(16):1475-1485.doi 10.1056/NEJMoa2407107
Discussion & critique
First non-steroidal MRA win in HFpEF/HFmrEF. Modest, hospitalisation-driven benefit; adds to SGLT2 inhibitors rather than replacing them.